Welcome to our dedicated page for Phio Pharmaceuticals news (Ticker: PHIO), a resource for investors and traders seeking the latest updates and insights on Phio Pharmaceuticals stock.
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company whose news flow centers on the development of its INTASYL® gene silencing technology and lead compound PH-762. Company announcements describe INTASYL as a gene silencing platform focused on immuno-oncology therapeutics, with PH-762 targeting the PD-1 gene implicated in various forms of skin cancer.
News about Phio frequently covers clinical trial milestones for PH-762. The company has reported completion of enrollment in its ongoing Phase 1b dose escalation trial (NCT 06014086), interim pathology results in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, and safety reviews by its Safety Monitoring Committee. Updates have included detailed response rates, such as complete, near complete, and partial responses based on tumor clearance, as well as statements that no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed in the cohorts reported.
Phio also issues regulatory and development updates, including acceptance by the U.S. Food and Drug Administration of its nonclinical protocol study design for a toxicology study required before a pivotal trial of PH-762. Additional news items describe agreements with a U.S. manufacturer for cGMP clinical supply of PH-762 and progress toward delivering commercially viable drug product.
Investors following PHIO news will also see financing and corporate announcements, such as warrant inducement transactions, cash runway commentary, and board-level changes, including the appointment of a Lead Independent Director. The company regularly participates in investor conferences and scientific meetings, where it presents INTASYL technology and PH-762 data, and has highlighted external recognition such as PH-762 being named “Immunomodulatory Solution of the Year” in the BioTech Breakthrough Awards.
This news page aggregates these clinical, regulatory, financing, and governance updates so readers can track how Phio’s INTASYL platform and PH-762 program are progressing over time.
Phio Pharmaceuticals (NASDAQ: PHIO) reported that the Safety Monitoring Committee completed its safety review of PH-762 in a Phase 1b skin cancer trial. No dose-limiting toxicities or serious adverse events were observed among 22 treated patients across five dose-escalation cohorts.
The highest dose cohort (n=7) showed an 85% pathological response (6 of 7), with 4 of 6 responders achieving complete tumor clearance. Overall cSCC response was 65% (13 of 20), including 9 complete responses. An FDA meeting submission is targeted for Q2 2026 and CMC API material is expected in March 2026 ahead of cGMP manufacturing in H2 2026.
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the 3rd Annual DealFlow Discovery Conference on January 28, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman, will deliver the company presentation on January 28 at 9:00 AM ET in Borgata Hotel Room #1, and management will be available for one-on-one investor meetings during the event.
The company noted completion of treatment in the Phase 1b trial for PH-762 and emphasized ongoing development of therapeutics using its proprietary INTASYL gene silencing technology targeting cancer.
Phio Pharmaceuticals (NASDAQ: PHIO) reported pathology and safety results from its Phase 1b intratumoral PH-762 dose‑escalation trial in cutaneous carcinomas on January 20, 2026. Across five cohorts, 22 patients completed treatment and excision; among 20 cSCC patients, 14 were pathologic responders (70% overall response): 10 complete responses (100% clearance), 2 near‑complete (>90%), and 2 partial (>50%). One metastatic Merkel cell patient had a partial (>50%) response. No dose‑limiting toxicities or clinically relevant treatment‑emergent adverse events were observed through the reported follow‑up. Drug concentration was escalated 20‑fold from first to final cohort. Extended safety follow‑up is expected in Q2 2026 and follow‑on trial design is underway.
Phio Pharmaceuticals (NASDAQ: PHIO) will present at the Sidoti Micro-Cap Virtual Investor Conference on January 22, 2026 at 1:45 PM ET. CEO and Chairman Robert Bitterman will provide an update on the company's proprietary INTASYL siRNA technology and progress in the ongoing clinical trial of lead compound PH-762 for treatment of skin cancers. The presentation is available via live webcast and the CEO will hold one-on-one investor meetings during the conference on Jan 21–22, 2026. Registration is free and open to non-clients.
Phio Pharmaceuticals (NASDAQ: PHIO) announced FDA acceptance of a nonclinical protocol for its INTASYL candidate PH-762 and said a required toxicology study will commence in Q1 2026. The company also said initiatives to produce commercially viable drug product under cGMP are ongoing and targeted for later in 2026, with part of recent financing directed to these efforts.
Interim Phase 1b results reported from 18 treated patients: among 16 cutaneous squamous cell carcinoma (cSCC) patients, there were 6 complete responses, 2 near-complete responses, and 2 partial responses; six cSCC and one metastatic melanoma showed pathologic non-response. No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects were observed to date.
Phio Pharmaceuticals (NASDAQ: PHIO) announced completion of enrollment in its Phase 1b trial of INTASYL siRNA lead PH-762 for cutaneous squamous cell carcinoma (cSCC), melanoma and Merkel cell carcinoma.
Key facts: 18 patients treated across five dose-escalating cohorts; in 16 cSCC patients there were 6 complete responses, 2 near-complete and 2 partial responses; one Merkel cell carcinoma patient had a partial response; no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported.
Additional patients are being treated in the fifth cohort at the highest dose and pathology results are expected in Q1 2026.
Phio Pharmaceuticals (NASDAQ: PHIO) will present a podium talk on its INTASYL siRNA Drug Technology at Advanced Therapies USA 2025 in Philadelphia on November 18, 2025. The presentation, titled "INTASYL® Synthesized siRNA Drug Technology Down-regulating Gene Expression," will be delivered by Melissa Maxwell, M.S. in the Innovation Showcase (Track 2, Seminar Theatre) at 1:15 PM EDT. The company described INTASYL and PH-762 as a promising approach to enhance cancer treatment and a potential non-surgical option for cutaneous carcinomas.
Event dates are November 18–19, 2025 at the Pennsylvania Convention Center.
Phio Pharmaceuticals (NASDAQ: PHIO) reported Q3 2025 results and a business update on November 13, 2025. Key clinical and financing developments include advancement to the fifth and final dose cohort for intratumoral INTASYL PH-762 and pathology at maximum dose showing 100% tumor clearance in 1 patient, >90% clearance in a second, and >50% clearance in a third at Day 36.
Cumulative cSCC results: 6 complete responses among 16 cSCC patients. No dose-limiting toxicities reported. The company completed warrant inducement financings expected to raise ~$12.1 million, and estimates cash of ~$21.3 million, projecting runway into H1 2027.
Phio Pharmaceuticals (NASDAQ: PHIO) will present clinical results from its ongoing Phase 1b trial of intratumoral INTASYL PH-762 at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), November 7-9, 2025.
The poster (Abstract #610) titled "PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinomas: A Clinical Study of INTASYL PH-762" will be presented by Mary Spellman, M.D. on Saturday, November 8, 2025 at the Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center.
The Phase 1b dose-escalation study evaluates safety and tolerability of intratumoral PH-762 in patients with cutaneous squamous carcinoma, Merkel cell carcinoma, and melanoma.
Phio Pharmaceuticals (NASDAQ: PHIO) announced on November 7, 2025 that its INTASYL compound PH-762 won the 2025 Immunomodulatory Solution of the Year award from the BioTech Breakthrough Awards program.
The company is a clinical-stage biopharmaceutical developer using its proprietary INTASYL siRNA gene‑silencing platform focused on cancer therapies. Company leadership highlighted PH-762 as an intratumoral immunotherapy intended to enhance cancer treatment efficacy, and the award organization noted PH-762 addresses a medical need for non‑surgical options for cutaneous carcinomas.
FAQ
What is the current stock price of Phio Pharmaceuticals (PHIO)?
What is the market cap of Phio Pharmaceuticals (PHIO)?
